Patents by Inventor Camille CORREIA

Camille CORREIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11465964
    Abstract: The present invention relates to an improved process for the preparation of metformin hydrochloride, an important drug in the first line treatment of Type II Diabetes.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: October 11, 2022
    Assignee: Merck Patent GmbH
    Inventors: Camille Correia, Renaud Poli, Serge Gerbaut, Marc Dittmann, David Maillard, Sebastian Haertner
  • Publication number: 20210040035
    Abstract: The present invention relates to an improved process for the preparation of metformin hydrochloride, an important drug in the first line treatment of Type II Diabetes.
    Type: Application
    Filed: February 5, 2019
    Publication date: February 11, 2021
    Applicant: Merck Patent GmbH
    Inventors: Camille CORREIA, Renaud POLI, Serge GERBAUT, Marc DITTMANN, David MAILLARD, Sebastian HAERTNER
  • Patent number: 9676735
    Abstract: The invention relates to a process for the preparation of Efavirenz via an efficient transition metal catalyzed cyclization, to a device suitable to perform such process as well as to novel intermediates.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: June 13, 2017
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Camille A. Correia, Kerry Gilmore, David Tyler McQuade, Peter H. Seeberger
  • Publication number: 20170057937
    Abstract: The invention relates to a process for the preparation of Efavirenz via an efficient transition metal catalyzed cyclization, to a device suitable to perform such process as well as to novel intermediates.
    Type: Application
    Filed: August 27, 2015
    Publication date: March 2, 2017
    Inventors: Camille A. Correia, Kerry Gilmore, David Tyler McQuade, Peter H. Seeberger